Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R HaasW Hunstein

Abstract

To evaluate the feasibility of a sequential high-dose therapy with peripheral-blood progenitor-cell (PBPC) support in patients with follicular lymphoma. Since July 1991, we have included 30 patients (17 men and 13 women) with a median age of 41 years (range, 26 to 55) in the study. At the time of study entry, 17 patients were in first and six in second or higher remission. Another six patients had relapse of disease and one had tumor progression. PBPC were collected during filgrastim-supported leukocyte recovery following high-dose cytarabine (ara-C)/mitoxantrone (HAM). A median of two leukaphereses (range, one to seven) resulted in a median of 5.7 x 10(6) CD34+ cells/kg (range, 2.9 to 23.7 x 10(6). A distinct population of B-lymphoid progenitors (CD34+/CD19+) was not detectable in the autografts, and the content of CD19+ B cells was remarkably low, comprising a median of 0.07% of the mononuclear cells. Using the polymerase chain reaction (PCR) assay for the major breakpoint regions (MBR) of the bcl-2/immunoglobulin H (IgH) translocation, 22 patients had autografts positive for the t(14;18) translocation, whereas seven patients had PCR-negative transplants. The autograft of one patient could not be assessed. Following myeloabla...Continue Reading

Citations

Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine SebbanBertrand Coiffier
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ApostolidisA Z Rohatiner
Nov 19, 2010·Expert Review of Hematology·Pier Paolo PiccalugaStefano A Pileri
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ApostolidisA Z Rohatiner
Sep 1, 1995·Medical Oncology·H Ratech
Oct 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry C SchoutenGunnar Kvalheim
Jan 1, 1997·Cancer Investigation·M R Bishop, A Kessinger
Apr 14, 2006·British Journal of Haematology·Donald W MilliganUNKNOWN Haematological Studies Group, UK National Cancer Research Institute

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
N T UenoR E Champlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sergio CortelazzoAlessandro Rambaldi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C R Kusnierz-GlazG D Long
© 2021 Meta ULC. All rights reserved